Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Jelly Force Male Enhancement Gummies Label Guide: 82 mg Proprietary Blend, Supplement Facts Panel, and 60-Day Guarantee Terms for 2026Jelly Force Male Enhancement Gummies discloses its formula, Supplement Facts panel, GMP manufacturing, and 60-day guarantee terms.
- York Space SystemsYork Space Systems to Present at Jefferies Global Industrials ConferenceDENVER, August 27, 2026--York Space Systems (York) (NYSE: YSS), today announced that Dirk Wallinger, CEO, will present at the 2026 Jefferies Global Industrials Conference in New York. During the course of this event, York may disclose material developments affecting its business and/or financial performance. Listeners may access the event via live audio webcast at ir.yorkspacesystems.com.
- Element Solutions IncElement Solutions Announces Mutual Termination of Merger Agreement with Solstice Advanced MaterialsMIAMI, August 27, 2026--Element Solutions Inc (NYSE: ESI) ("Element Solutions" or the "Company"), a global and diversified specialty chemicals technology company, today announced that the merger agreement between Element Solutions and Solstice Advanced Materials Inc. ("Solstice") has been mutually terminated.
- Forgent Power Solutions, Inc.Forgent Power Solutions, Inc. to Report Fiscal Fourth Quarter and Full Year 2026 ResultsDAYTON, Minn., August 27, 2026--Forgent Power Solutions, Inc. (NYSE: FPS), a leading designer and manufacturer of electrical distribution equipment used in data centers, the power grid and energy-intensive industrial facilities, will report financial results for its fiscal fourth quarter and full year ended June 30, 2026, before the market opens on September 15, 2026, and management will host a conference call at 11:00 a.m. ET to discuss the results.
- AeroVironment, Inc.AV to Present at the 2026 Jefferies Global Industrials ConferenceARLINGTON, Va., August 27, 2026--AeroVironment, Inc. ("AV") (NASDAQ: AVAV) will participate in the upcoming 2026 Jefferies Global Industrials Conference in New York City, New York. AV Chairman, President and Chief Executive Officer Wahid Nawabi and Executive Vice President and Chief Financial Officer Sean Woodward will participate in a fireside chat on September 10 at 12:50 p.m.
- Oryon Cell TherapiesOryon Cell Therapies Appoints Kenny Choi, Ph.D. as Chief Technical OfficerWATERTOWN, Mass., August 27, 2026--Oryon Cell Therapies ("Oryon"), a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegenerative disorders, today announced the appointment of Kenny Choi, Ph.D., as Chief Technical Officer (CTO). Dr. Choi will lead Oryon’s technical operations and Chemistry, Manufacturing, and Controls (CMC) strategy, including transfer of the manufacturing process for the company’s autologo
- The World's Leading Minds in Biotechnology Will Meet in Riyadh This SeptemberRIYADH, KSA, Aug 28, 2026 - The Riyadh Global Medical Biotechnology Summit has published the scientific program for its fourth edition, and the names on it belong to the people currently deciding what medicine will be able to do in the next twenty years. Sixty confirmed speakers and moderators from eleven countries are named across three days, from 14 to 16 September 2026, at the Sofitel Riyadh Hotel and Convention Centre. Among them are Prof. Jin-Soo Kim of KAIST, whose work on mitochondrial DNA editing reaches beyond CRISPR; Dr. Matthew H. Porteus of Stanford University, engineering genetic circuits into cell-based medicines; Dr. Alex Shalek of MIT; Prof. Vijay Kuchroo of Harvard Medical School; Prof. Keith T. Flaherty of the Massachusetts General Hospital Cancer Center and President of the American Association for Cancer Research; Prof. George F. Gao of the Chinese Academy of Sciences; President Mitsuo Ochi of Hiroshima University; and Dr. Zdenko Herceg of the International Agency for Research on Cancer. They are joined by the people who move science into the world. Dr. Steve Yang, Co-CEO of WuXi AppTec, and Mr. Alec Reynolds of Flagship Pioneering open the program on global partnership. Mr. Kasim Kutay, Chief Executive Officer of Novo Holdings, speaks on where capital should go next. Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, delivers the closing keynote. Alongside them stand the Saudi institutions building a biotechnology sector in real time: KAIMRC, Lifera, HUMAIN, SPIMACO, KAUST, the Saudi Food and Drug Authority, and Astronaut Rayyanah Barnawi on what the human immune system does in space. The program runs across six tracks: artificial intelligence in biotechnology, multi-omics, biotech investment, immunology, bioengineering and synthetic biology, and biotech workforce development. Its defining feature is that discovery and delivery share the same stage. Genome editing and population genomics sit beside regulation, domestic manufacturing, and procurement, and in several sessions the scientists and the regulators are on the same panel. That is the premise of the Kingdom's National Biotechnology Strategy, which targets $34.6 billion in non-oil GDP from biotechnology by 2040: a discovery is worth only as much as the system available to carry it to a patient. "Biotechnology is where the health of every nation will be decided over the next twenty years. Saudi Arabia has chosen not to watch that happen from a distance. We are building the laboratories, the manufacturing, the regulatory ecosystems, and above all, the bio-workforce talent. And we are building it in partnership with the world, under one roof. That is what this Summit is for. Its themes highlight where medicine and biotechnology converge to shape the future of biosciences. Discoveries and breakthroughs are transforming how we care for patients. The diversity of emerging technologies and therapies is creating significant opportunities to explore, advance, invest, and translate scientific progress into better health outcomes. Please join us in Riyadh this September." H.E. Prof. Bandar bin Abdulmohsen Al-Knawy, Chief Executive Officer of Health Affairs, Ministry of National Guard, and President, King Saud bin Abdulaziz University for Health Sciences The Summit is organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Abdullah International Medical Research Center (KAIMRC) and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), with the Ministry of Investment and Invest Saudi serving as strategic partners. The fourth edition is expected to welcome more than 15,000 visitors, over 200 biotechnology and healthcare brands, and delegations from more than 70 countries, under the theme Building the Foundations of Biotechnology Excellence. The full scientific program is attached and available at rgmbs.org, where registration is open for delegates, exhibitors, and industry partners. Follow the Summit at #RGMBS2026. For further information regarding summit programing visit: https://rgmbs.org/program#conference-agenda About the Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition takes place from 14 to 16 September 2026 in Riyadh. For Media Inquiry Email: [email protected] Telephone: +966 559 810 777
- The Government of CanadaKardium Receives Funding From the Government of Canada to Expand Manufacturing of the Globe® Pulsed Field System in British ColumbiaVANCOUVER, British Columbia, August 27, 2026--The Government of Canada today announced funding of up to $31.25 million through the Strategic Response Fund (SRF) toward Kardium’s investment in a $125 million project to expand its manufacturing capabilities in Vancouver, British Columbia.
- Confirming the Relevance of AFYREN’s Business Model and Advancing the Industrial Production Ramp-upCLERMONT-FERRAND, France & LYON, France, August 27, 2026--Regulatory News: AFYREN, a greentech company offering manufacturers biobased, low-carbon ingredients through a unique fermentation technology based on a circular model, provides an update on the operational performance of its AFYREN NEOXY plant and shares its outlook for the second half of 2026.
- The World's Leading Minds in Biotechnology Will Meet in Riyadh This SeptemberRIYADH, KSA, Aug 28, 2026 - The Riyadh Global Medical Biotechnology Summit has published the scientific program for its fourth edition, and the names on it belong to the people currently deciding what medicine will be able to do in the next twenty years. Sixty confirmed speakers and moderators from eleven countries are named across three days, from 14 to 16 September 2026, at the Sofitel Riyadh Hotel and Convention Centre. Among them are Prof. Jin-Soo Kim of KAIST, whose work on mitochondrial DNA editing reaches beyond CRISPR; Dr. Matthew H. Porteus of Stanford University, engineering genetic circuits into cell-based medicines; Dr. Alex Shalek of MIT; Prof. Vijay Kuchroo of Harvard Medical School; Prof. Keith T. Flaherty of the Massachusetts General Hospital Cancer Center and President of the American Association for Cancer Research; Prof. George F. Gao of the Chinese Academy of Sciences; President Mitsuo Ochi of Hiroshima University; and Dr. Zdenko Herceg of the International Agency for Research on Cancer. They are joined by the people who move science into the world. Dr. Steve Yang, Co-CEO of WuXi AppTec, and Mr. Alec Reynolds of Flagship Pioneering open the program on global partnership. Mr. Kasim Kutay, Chief Executive Officer of Novo Holdings, speaks on where capital should go next. Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, delivers the closing keynote. Alongside them stand the Saudi institutions building a biotechnology sector in real time: KAIMRC, Lifera, HUMAIN, SPIMACO, KAUST, the Saudi Food and Drug Authority, and Astronaut Rayyanah Barnawi on what the human immune system does in space. The program runs across six tracks: artificial intelligence in biotechnology, multi-omics, biotech investment, immunology, bioengineering and synthetic biology, and biotech workforce development. Its defining feature is that discovery and delivery share the same stage. Genome editing and population genomics sit beside regulation, domestic manufacturing, and procurement, and in several sessions the scientists and the regulators are on the same panel. That is the premise of the Kingdom's National Biotechnology Strategy, which targets $34.6 billion in non-oil GDP from biotechnology by 2040: a discovery is worth only as much as the system available to carry it to a patient. "Biotechnology is where the health of every nation will be decided over the next twenty years. Saudi Arabia has chosen not to watch that happen from a distance. We are building the laboratories, the manufacturing, the regulatory ecosystems, and above all, the bio-workforce talent. And we are building it in partnership with the world, under one roof. That is what this Summit is for. Its themes highlight where medicine and biotechnology converge to shape the future of biosciences. Discoveries and breakthroughs are transforming how we care for patients. The diversity of emerging technologies and therapies is creating significant opportunities to explore, advance, invest, and translate scientific progress into better health outcomes. Please join us in Riyadh this September." H.E. Prof. Bandar bin Abdulmohsen Al-Knawy, Chief Executive Officer of Health Affairs, Ministry of National Guard, and President, King Saud bin Abdulaziz University for Health Sciences The Summit is organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Abdullah International Medical Research Center (KAIMRC) and King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), with the Ministry of Investment and Invest Saudi serving as strategic partners. The fourth edition is expected to welcome more than 15,000 visitors, over 200 biotechnology and healthcare brands, and delegations from more than 70 countries, under the theme Building the Foundations of Biotechnology Excellence. The full scientific program is attached and available at rgmbs.org, where registration is open for delegates, exhibitors, and industry partners. Follow the Summit at #RGMBS2026. For further information regarding summit programing visit: https://rgmbs.org/program#conference-agenda About the Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition takes place from 14 to 16 September 2026 in Riyadh. For Media Inquiry Email: [email protected] Telephone: +966 559 810 777
- Overseas Growth Gathers Momentum as CanSinoBIO's Global Strategy Unlocks New OpportunitiesCanSino Biologics Inc. (“CanSinoBIO,” 06185.HK/688185.SH) released its financial results for the first half of 2026. The Company reported revenue of approximately RMB 550 million, up 43.8% year on year, while its net loss attributable to shareholders narrowed significantly. Notably, while demand in China’s vaccine market remains challenging, CanSinoBIO’s international business maintained strong growth momentum, generating overseas revenue of RMB 150 million during the reporting period. As established products accelerate their expansion into overseas markets, and collaboration models such as technology partnerships and localized industrialization continue to take shape, CanSinoBIO’s overseas business is evolving from a strategic initiative into an increasingly important contributor to the Company’s performance. This reflects the Company’s forward-looking understanding of global vaccine market trends and evolving demand in international markets. At a time when the vaccine industry is facing changes in demand structure, the combination of domestic innovation capabilities and access to international markets is becoming an increasingly important measure of corporate growth resilience. Overseas Growth Accelerates In the first half of 2026, China’s vaccine industry continued to face demand-side pressure. As the target population for infant and young-child vaccination continues to decline, demand pressure on traditional pediatric vaccines has become increasingly visible. “Volume contraction and price decline” has emerged as a widespread challenge across the industry. Based on disclosed financial results across the sector, this pressure appears to be industry-wide. In 2025, Zhifei Biological generated RMB1.187 billion in revenue from self-developed products, up 1.23% year on year. Walvax Biotechnology reported 2025 revenue of RMB2.418 billion, down 14.29% year on year; despite a 53.36% year-on-year increase in batch-release volume for its core 13-valent pneumococcal conjugate vaccine, revenue remained under pressure. Kangtai Biological reported revenue of RMB1.273 billion in the first half of 2026, down 8.55% year on year. Against this industry backdrop, the growth of CanSinoBIO’s international business is particularly noteworthy. The Company reported overseas revenue of RMB 150 million in the first half of 2026. This growth was driven, on the one hand, by the continued expansion of mature products into overseas markets and, on the other, by the further deepening of the Company’s international partnership models. For CanSinoBIO, this also means that its products, manufacturing processes and quality control capabilities, validated in the domestic market, are beginning to unlock value overseas through more diversified approaches. Meanwhile, the Company continues to advance its international market footprint. Registration filings and commercialization efforts remain underway across Southeast Asia, South America and the Middle East. Menhycia(R) has obtained registration approvals in Indonesia and Argentina, and product supply has already commenced in Indonesia. As more products progress through overseas registration and commercialization, CanSinoBIO’s international business is expected to develop more diversified revenue streams and further strengthen its commercial resilience. From this perspective, CanSinoBIO’s globalization strategy is evolving. Overseas markets are no longer merely destinations for mature products, but are increasingly becoming markets in which products, technologies and industrial capabilities can jointly create value. For an innovative vaccine company, this shift from “exporting products” to “exporting capabilities and systems” creates greater room for long-term growth in its overseas business. Portfolio Upgrades Strengthen the Commercial Foundation Sustained overseas expansion is underpinned by a stable product portfolio and strong technological capabilities. According to the Company’s interim report, domestic revenue continued to grow despite factors such as changes in value-added tax, reflecting opportunities created by ongoing innovation. Menhycia(R), China’s first quadrivalent meningococcal conjugate vaccine, expanded its indicated population in February to children aged 3 months to 6 years, broadening its addressable population. Meanwhile, iPneucia(R), a 13-valent pneumococcal conjugate vaccine featuring dual-carrier technology (CRM197/TT), offers a differentiated option for pediatric pneumococcal disease prevention in China. Since its launch in September 2025, iPneucia(R) has continued to expand market access and is now available in nearly 30 provincial-level markets across China. From meningococcal disease to pneumococcal disease, CanSinoBIO is using innovative products to address vaccine segments that continue to offer meaningful unmet demand. As traditional vaccine categories face pressure on volumes, structural growth driven by product and technology upgrades is providing important support for the Company’s commercial resilience. More importantly, the product-development and industrialization capabilities established in the domestic market also provide a foundation for overseas expansion. For an innovative vaccine company, successful commercialization in China not only broadens revenue sources, but also validates the manufacturing, quality-control and supply systems required to replicate and extend those capabilities into international markets. Domestic product upgrades and overseas business growth are thereforeclosely connected rather than separate. The former provides the foundation in products and technologies, while the latter expands the geographic boundaries within which those products can realize their value. Multi-Layered Pipeline Takes Shape to Support Future Growth For an innovative vaccine company, long-term growth depends not only on the commercial performance of existing products, but also on the ability to maintain a steady flow of new products. By pursuing continued ramp-up of marketed products, advancing products under regulatory review and developing next-generation candidates, CanSinoBIO is building a more sustainable and well-sequenced product pipeline. Tripecia(R) (DT3cP Infant), CanSinoBIO’s three-component acellular diphtheria, tetanus and pertussis combined vaccine for infants, received NDA approval in April 2026, becoming the first approved three-component DTP vaccine in China. In August 2026, the first commercial batches received the Certificate for Batch Release of Biological Products. Provincial tendering and market-access processes are progressing in an orderly manner, and the product has begun entering the market supply stage. While Tripecia(R) represents an upgrade in pertussis vaccination for infants, the Td5cp vaccine for adolescents and adults — which has also been granted Priority Review status — is expected to extend CanSinoBIO’s pertussis vaccine portfolio to a broader population. The New Drug Application for Td5cp has been accepted by China’s National Medical Products Administration (NMPA). In addition, CanSinoBIO’s independently developed Adsorbed Tetanus Vaccine, Tetcia(R), has been formally approved, further strengthening the Company’s adult vaccine portfolio. From infants to adolescents and adults, and from individual products to a multi-product portfolio, this strategy is broadening the foundation for future commercial growth. In pneumococcal vaccines, CanSinoBIO’s 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (PCV24) formally initiated Phase I/II clinical trials in May 2026, and participant enrollment across different cohorts is progressing as planned. At the same time, the Company continues to advance development of its DT3cP-Hib-MCV4 combination vaccine, extending its portfolio toward increasingly multivalent and combination vaccine formats. Over the longer term, CanSinoBIO is continuing to build its mRNA platform and explore applications in preventive vaccines and therapeutic biologics. The Company is conducting early-stage research into mRNA applications for glioblastoma, rhabdomyosarcoma and cervical cancer, while also exploring in vivo CAR therapies. These programs remain at an early stage, with the Company continuing to assess the potential of mRNA and related technologies in disease treatment. Additionally, on August 25, CanSinoBIO announced that its subsidiary, CanSino Shanghai, had entered a strategic collaboration with deepGeneAI on mRNA therapeutic cancer vaccines. The two parties will leverage their respective strengths in mRNA vaccine technology and tumor neoantigen discovery and design to jointly advance the development and commercialization of personalized mRNA therapeutic cancer vaccines. These pipeline programs represent extensions of CanSinoBIO’s existing technology platforms and product-development experience. The Company’s core platforms — including viral vector vaccines, synthetic vaccines, protein structure design and VLP assembly, mRNA vaccines, as well as formulation and delivery technologies — provide a foundation for continued product iteration and technology translation. Innovation Supports Long-Term Development Viewed in the context of its 2026 interim results, CanSinoBIO’s story is not simply one of revenue growth. Against a changing domestic vaccine demand structure, innovative products have continued to deliver solid commercial performance, demonstrating the resilience created by product upgrades. Overseas business model expanded beyond finished-product exports to include technology collaboration and local manufacturing capabilities, indicating that international markets are becoming a new source of growth. At the same time, Tripecia(R) has entered the market supply stage, the Td5cp vaccine for adolescents and adults is progressing through regulatory review, and pipeline programs including PCV24, multivalent and combination vaccines, and mRNA technologies continue to advance, providing both product succession and technology reserves for the future. These three pathways ultimately point to the same growth logic: domestic innovation capabilities form the product foundation, overseas expansion broadens the commercial opportunity, and sustained R&D determines whether growth can continue over the long term. In an environment where demand for traditional vaccines is under pressure and industry competition is intensifying, growth is increasingly shifting away from reliance on product-volume expansion alone and toward a model jointly driven by product upgrades, technological innovation and global markets. For CanSinoBIO, continued growth in the overseas business is providing increasingly visible financial evidence of this transition. As more innovative products enter the market, more mature products expand overseas and the Company’s technical capabilities extend further into international value chains, CanSinoBIO’s growth runway is expanding from a single domestic market to the global market. For the Company, internationalization is not only about broadening geographic reach; it is also an important pathway for innovative products and technologies to realize greater commercial value while contributing to global public health.
- Nexteer; Phoenix InvestorsPHOENIX INVESTORS AND NEXTEER AUTOMOTIVE ANNOUNCE COMPLETION OF 1.8 MILLION-SQUARE-FOOT, THREE-BUILDING INDUSTRIAL PROPERTY TRANSACTION IN SAGINAW, MICHIGANAcquisition supports Nexteer's continued manufacturing operations while creating significant new investment, redevelopment, and leasing opportunities in Buena Vista Charter Township — An affiliate of Milwaukee-based Phoenix Investors...